Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

on behalf of the REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry